文献速递淋巴瘤

拉丁美洲外周T细胞淋巴瘤的流行病学、临床特征与结局:一项国际回顾性队列研究

Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study.
PubMed 文献 · Lancet Haematol · 2025-03-05

该国际回顾性队列研究纳入拉丁美洲11国2000年至2023年新诊断外周T细胞淋巴瘤成人患者,分析亚型分布与生存结局。1979例纳入分布分析,1349例纳入治疗与结局分析;中位随访36个月,3年总生存率40%(95%CI 38-44)。拉丁美洲以外周T细胞淋巴瘤非特指型最常见(35%),成人T细胞白血病/淋巴瘤和结外NK/T细胞淋巴瘤比例较高。

要点

  • 拉丁美洲外周T细胞淋巴瘤最常见亚型为外周T细胞淋巴瘤非特指型(35%)。
  • 成人T细胞白血病/淋巴瘤在秘鲁(39%)和哥伦比亚(29%)比例较高。
  • 结外NK/T细胞淋巴瘤在中美洲和加勒比(41%)及墨西哥(31%)比例较高。

核心结论

  • 拉丁美洲外周T细胞淋巴瘤具有独特流行病学特征,成人T细胞白血病/淋巴瘤和结外NK/T细胞淋巴瘤患病率较高。
  • 作者认为这些发现为优先开展这些罕见亚型的临床试验提供了重要机会,应将拉丁美洲国家纳入全球研究。
  • 作者指出其发现需要在稳健的流行病学研究中进一步验证。

研究设计与样本

  • 国际回顾性队列研究,纳入拉丁美洲11个国家(阿根廷、巴西、智利、哥伦比亚、古巴、危地马拉、墨西哥、巴拉圭、秘鲁、乌拉圭和委内瑞拉)年龄≥18岁的新诊断外周T细胞淋巴瘤患者。
  • 数据来源包括拉丁美洲淋巴增殖性疾病研究组医院登记(回顾性,2000年1月1日至2023年6月30日)、巴西T细胞项目(2015年1月1日至2017年6月30日为回顾性,2017年7月1日至2023年6月30日为前瞻性)和国际T细胞淋巴瘤项目(前瞻性登记)。
  • 1979例经病理诊断的外周T细胞淋巴瘤患者纳入分布分析,1349例纳入治疗模式和结局分析。

主要发现

  • 诊断时中位年龄54岁(IQR 41-67);1794例患者中女性733例(41%),男性1061例(59%)。
  • 1979例患者中最常见亚型为外周T细胞淋巴瘤非特指型(688例,35%),其次为成人T细胞白血病/淋巴瘤(333例,17%)和结外NK/T细胞淋巴瘤(291例,15%)。
  • 其他亚型包括ALK阴性间变性大T细胞淋巴瘤(186例,9%)、成熟T细胞淋巴瘤非特指型(163例,8%)、血管免疫母细胞性T细胞淋巴瘤(123例,6%)和ALK阳性间变性大T细胞淋巴瘤(73例,4%)。
  • 成人T细胞白血病/淋巴瘤比例在秘鲁较高(414例中158例,39%;p<0.0001),在哥伦比亚也较高(58例中17例,29%;p=0.011);结外NK/T细胞淋巴瘤比例在中美洲和加勒比较高(255例中105例,41%;p<0.0001),在墨西哥也较高(70例中22例,31%;p<0.0001)。
  • 分析队列中位随访36个月(IQR 12-60),观察到674例死亡,3年总生存率为40%(95%CI 38-44)。

关键数值与推荐

  • 3年总生存率总体为40%(95%CI 38-44)。
  • ALK阳性间变性大T细胞淋巴瘤3年总生存率77%(95%CI 66-90),ALK阴性间变性大T细胞淋巴瘤55%(95%CI 46-65),结外NK/T细胞淋巴瘤48%(95%CI 42-56)。
  • ALK阴性间变性大T细胞淋巴瘤中CHOEP/EPOCH组3年总生存率67%(95%CI 56-81),CHOP组41%(95%CI 26-65),p=0.018。
  • 成人T细胞白血病/淋巴瘤中CHOEP/EPOCH组3年总生存率20%(95%CI 11-38),CHOP组18%(95%CI 12-27),p=0.0087。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出其发现需要在稳健的流行病学研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral T-cell lymphomas represent a rare and heterogeneous group of mature T-cell neoplasms characterised by aggressive behavior. Previous studies evaluating peripheral T-cell lymphoma epidemiology across Latin America have been restricted in their representation of most countries in the region. In this study, we aimed to describe peripheral T-cell lymphoma epidemiology across Latin America. METHODS: We did an international, retrospective, cohort study of patients (aged ≥18 years) with newly diagnosed peripheral T-cell lymphoma across 11 countries in Latin America (Argentina, Brazil, Chile, Colombia, Cuba, Guatemala, Mexico, Paraguay, Peru, Uruguay, and Venezuela). We used the hospital-based registries of the Grupo de Estudio Latinoamericano de Linfoproliferativos (retrospective registry; Jan 1, 2000, to June 30, 2023), the Brazilian T-cell Project (retrospective from Jan 1, 2015, to June 30, 2017 and prospective from July 1, 2017, to June 30, 2023), and the International T-cell Lymphoma Project (prospective registry). The main outcomes were prevalence of peripheral T-cell lymphoma subtypes, overall survival, estimated using the Kaplan-Meier method, and objective response rate. Survival probabilities were estimated using the Kaplan-Meier method and compared with the log-rank test. Overall response rate was calculated by summing complete and partial responses, with 95% CIs estimated using the Clopper-Pearson method. FINDINGS: 1979 patients diagnosed with peripheral T-cell lymphoma by pathology, between 2000 and 2023, met our inclusion criteria for the distribution analysis and 1349 were included in the treatment patterns and outcome analysis. Median age at diagnosis was 54 years (IQR 41-67), 733 (41%) of 1794 patients were female, and 1061 (59%) patients were male. The most common subtype was peripheral T-cell lymphoma, not otherwise specified (688 [35%] of 1979 patients); the second and third most frequent subtypes were adult T-cell leukaemia or lymphoma (333 [17%] of 1979 patients) and extranodal natural killer T-cell lymphoma (291 [15%] of 1979 patients). The next most common subtypes were ALK-negative anaplastic large T-cell lymphoma (186 [9%] of 1979 patients), mature T-cell lymphoma, not otherwise specified (163 [8%] of 1979), angioimmunoblastic T-cell lymphoma (123 [6%] of 1979 patients), and ALK-positive anaplastic large T-cell lymphoma (73 [4%] of 1979 patients). The observed proportion of people with adult T-cell leukaemia or lymphoma was higher in Peru (158 [39%] of 414 patients; p<0·0001) and Colombia (17 [29%] of 58 patients; p=0·011), whereas the percentage for extranodal natural killer T-cell lymphoma was higher in Central America and the Caribbean (105 [41%] of 255 patients; p<0·0001) and Mexico (22 [31%] of 70 patients; p<0·0001). With a median follow-up of 36 months (IQR 12-60) in the analytical cohort, we observed 674 deaths, and 3-year overall survival was 40% (95% CI 38-44). ALK-positive anaplastic large T-cell lymphoma had the highest survival outcomes, with 11 deaths and a 3-year overall survival of 77% (95% CI 66-90), followed by ALK-negative anaplastic large T-cell lymphoma (52 deaths and 3-year overall survival of 55%, 95% CI 46-65) and extranodal natural killer T-cell lymphoma (108 deaths and 3-year overall survival of 48%, 95% CI 42-56). The use of CHOEP (cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone) or EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) was associated with superior 3-year overall survival compared with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) among patients with ALK-negative anaplastic large T-cell lymphoma (20 deaths; 67%, 95% CI 56-81 vs 16 deaths; 41%, 26-65; p=0·018) and adult T-cell leukaemia or lymphoma (45 deaths; 20%, 11-38 vs 100 deaths; 18%, 12-27; p=0·0087), but not for all other subtypes. INTERPRETATION: Our study underscores the unique epidemiological profile of peripheral T-cell lymphoma in Latin America, with a high prevalence of adult T-cell leukaemia or lymphoma and extranodal natural killer T-cell lymphoma. These findings present a crucial opportunity to prioritise clinical trials on these rare subtypes of peripheral T-cell lymphoma by integrating Latin American countries into global research. However, our findings require further validation in robust epidemiological studies. FUNDING: American Society of Hematology Harold Amos Medical Faculty Development Program Award and the Robert A Winn Diversity in Clinical Trials Program Award. TRANSLATIONS: For the Portuguese and Spanish translations of the abstract see Supplementary Materials section.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Malpica L, Idrobo H, Pavlovsky A, et al. Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study. Lancet Haematol. 2025. PMID: 40056928. doi:10.1016/S2352-3026(25)00011-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。